CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
Muhammad Usama TariqMuhammad FurqanHira ParveenRahim UllahMuhammad MuddassarRahman Shah Zaib SaleemVassilios BavetsiasSpiros LinardopoulosAmir FaisalPublished in: British journal of cancer (2021)
Our results demonstrate that CCT245718 is a potent dual FLT3/Aurora A inhibitor that can overcome TKD-mediated acquired resistance.